|1.||Jänne, Pasi A: 72 articles (12/2015 - 09/2002)|
|2.||Mitsudomi, Tetsuya: 69 articles (01/2016 - 12/2004)|
|3.||Ciardiello, Fortunato: 66 articles (10/2015 - 06/2002)|
|4.||Zhang, Li: 58 articles (12/2015 - 11/2002)|
|5.||Pao, William: 56 articles (05/2015 - 02/2004)|
|6.||Hirsch, Fred R: 55 articles (12/2015 - 02/2002)|
|7.||Kris, Mark G: 47 articles (12/2015 - 06/2003)|
|8.||Kiura, Katsuyuki: 47 articles (03/2015 - 01/2004)|
|9.||Baselga, José: 46 articles (04/2015 - 01/2002)|
|10.||Yatabe, Yasushi: 46 articles (03/2015 - 05/2004)|
|1.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
08/11/2015 - "Targeting these driver mutations, such as sensitizing epidermal growth factor receptor (EGFR) mutations, has dramatically improved the prognosis of advanced non-small cell lung cancer (NSCLC). "
03/01/2012 - "Applying a previously developed non-small cell lung cancer model, we assess 'cross-scale' the therapeutic efficacy of targeting a variety of molecular components of the epidermal growth factor receptor (EGFR) signalling pathway. "
11/01/2010 - "Therapeutic agents directed against the epidermal growth factor receptor (EGFR) signaling pathway have been effective in the treatment of non-small cell lung cancer (NSCLC). "
04/01/2009 - "Epidermal growth factor receptor (EGFR) inhibitors are effective in a subset of patients with non-small-cell lung cancer (NSCLC). "
09/01/2010 - "The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations."
04/01/2014 - "Most SCAC tumors overexpress epidermal growth factor receptor (EGFR); therefore, it is reasonable to consider anti-EGFR drugs as a new treatment option, as demonstrated by anecdotal reports. "
10/15/2008 - "Targeted therapy against human epidermal growth factor receptor 2 (anti-HER-2) is very effective in tumors that overexpress HER-2/neu receptors, but cost largely prevents its use in resource-limited environments. "
01/01/2015 - "Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is associated with an aggressive form of the disease with significantly shortened disease free and overall survival. "
08/01/2013 - "The identification of the human epidermal growth factor receptor 2 (HER2) as a targetable marker of adverse prognosis along with the development of HER2-directed therapies, have significantly improved outcomes for women with HER2-overexpressing breast cancers. "
04/01/1991 - "Epidermal growth factor receptor binding was significantly greater in lung-tumor samples (31.38%) compared with that in normal lung tissue (3.76%). "
|3.||Breast Neoplasms (Breast Cancer)
12/22/2015 - "Blockade of human epidermal growth factor receptor type 2 (HER2) has dramatically improved outcome for patients with HER2-positive breast cancer. "
11/01/2015 - "The development of human epidermal growth factor receptor 2 (HER2)-targeting agents for the treatment of HER2-amplified breast cancer has dramatically improved outcomes for patients with this disease. "
05/10/2014 - "The highly effective treatment of human epidermal growth factor receptor (HER) 2-amplified breast cancer has proven challenging because of a signal buffering capacity inherent in the functionally relevant HER2-HER3 target. "
04/01/2014 - "The discovery of human epidermal growth factor receptor 2 (HER2) and its role in the biology of breast cancer, and the subsequent development of HER2-targeted therapies, have dramatically improved clinical outcomes for millions of women with early-stage and advanced HER2-positive breast cancer. "
02/01/2014 - "To review the most recent developments in the treatment of human epidermal growth factor receptor type 2 (HER2)-positive breast cancer with novel HER2-targeting agents and combinations that have significantly improved clinical outcomes. "
|4.||Colorectal Neoplasms (Colorectal Cancer)
09/01/2012 - "For metastatic colorectal cancer (mCRC) patients anti-EGFR (epidermal growth factor receptor) targeted therapy has markedly improved disease control and survival. "
03/01/2012 - "The identification of KRAS and BRAF mutations as predictive molecular alterations of resistance to EGF receptor monoclonal antibody therapy in metastatic colorectal cancer have significantly improved the selection of patients more likely to be eligible for the treatment with these targeted agents. "
03/01/2012 - "Epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridisation (FISH) can discriminate among KRAS wild-type patients those with better outcome to EGFR-targeted therapy in metastatic colorectal cancer, further enhancing selection of patients. "
01/22/2015 - "The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. "
12/01/2009 - "Targeted therapy against the EGF receptor was shown to be effective in a subgroup of patients with KRAS wild-type colorectal cancer. "
|5.||Lung Neoplasms (Lung Cancer)
09/01/2013 - "A minimally invasive and repeatable approach for real-time epidermal growth factor receptor (EGFR) mutation surveillance would be highly beneficial for individualized therapy of late stage lung cancer patients whose surgical specimens are often not available. "
01/01/2014 - "The high efficacy of crizotinib in ALK- and ROS-positive lung cancer as new molecular targets beside the epidermal growth factor receptor (EGFR) underscores the importance of molecular typing in NSCLC."
06/01/2015 - "Epidermal growth factor receptor (EGFR) mutations can affect the therapeutic efficacy of drugs used to treat nonsmall-cell lung cancer (NSCLC). "
07/01/2011 - "Preclinical results show that afatinib is effective in lung cancer models, including those with EGF receptor (EGFR) mutations resistant to reversible first-generation EGFR inhibitors. "
07/15/2006 - "Inhibitors targeting the epidermal growth factor receptor (EGFR) are effective in a subset of non-small cell lung cancers. "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|4.||erlotinib (CP 358,774)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|8.||Epidermal Growth Factor (EGF)
|1.||Drug Therapy (Chemotherapy)
|3.||Heterologous Transplantation (Xenotransplantation)